0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV165.96%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-4DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Organogenesis Stock Discussion
of $2.3 million compared to net revenue of $107.6 million for the first
quarter of 2023. Net revenue for the first quarter of 2024 consists of:
-- Net revenue from Advanced Wound Care products of $103.9 million,
an increase of 3% from the first quarter of 2023.
-- Net revenue from Surgical & Sports Medicine products of $6.1
million, a decrease of 9% from the first quarter of 2023.
-- Net loss of ...
Organogenesis Holdings Inc., a frontrunner in the regenerative medicine landscape, has recently shared groundbreaking results from its Phase 3 clinical trial for ReNu®, a cutting-edge therapy designed for knee osteoarthritis (OA) management. The trial's positive top line data underscore a pivotal moment in pain management and regen...
NEWS
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis
Organogenesis announced positive top-line data from its Phase 3 clinical trial of ReNu for knee osteoarthritis, achieving a statistically significant reduction in knee pain and maintenance of function at six months. The results open a transformative opportunity for Organogenesis to enter the pain management market. ReNu addresses a critical unmet medical need for knee ...
NOT EAGLES FOOD FOR GOOSE, DUCK AND CHICKEN... 😋
No comment yet